[Treatment Algorithm of Pulmonary Arterial Hypertension]

Targeted therapy for pulmonary arterial hypertension has a positive impact on the symptoms and prognosis of the disease. Targeted and early combination therapy demonstrates greater improvements compared to monotherapy. For treatment decisions, assessing the mortality risk based on risk stratification and the presence of comorbidities is essential. A low-risk status is desirable, but does not always guarantee long-term clinically stable disease. Therefore, early and regular reevaluations should be performed to monitor treatment response, determining the therapeutic consequences for treatment adjustment.Novel agents and the discovery of new mechanisms of action have greatly expanded and improved treatment options, but require further evaluation in long-term studies. The definition of new treatment goals, such as achieving remission of PAH, should be critically discussed among the new therapeutic options and further evaluated through prospective studies 1.